Kite Pharma, Inc.

Kite Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Gilead Sciences, Inc., and therefore, any climate commitments or emissions data may be cascaded from its parent organisation.

Kite Pharma has not outlined any specific reduction targets or initiatives in its own documentation. However, it is important to note that it inherits sustainability and climate-related initiatives from Gilead Sciences, Inc. This includes participation in various climate frameworks such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are associated with Gilead Sciences at the first cascade level.

As a subsidiary, Kite Pharma's climate commitments and performance metrics are likely aligned with Gilead's broader sustainability goals, although specific details regarding emissions reductions or targets have not been disclosed. The absence of direct emissions data highlights the need for further transparency in reporting and commitment to climate action within the biopharmaceutical sector.